Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome

被引:18
作者
Adamzik, Michael [1 ,2 ]
Frey, Ulrich H. [1 ,2 ]
Riemann, Kathrin [2 ]
Sixt, Stephan [1 ]
Lehmann, Nils [3 ]
Siffert, Winfried [2 ]
Peters, Juergen [1 ]
机构
[1] Univ Klinikum Essen, Univ Duisburg Essen, Klin Anasthesiol & Intens Med, Essen, Germany
[2] Univ Klinikum Essen, Univ Duisburg Essen, Inst Pharmakogenet, Essen, Germany
[3] Univ Klinikum Essen, Univ Duisburg Essen, Inst Med Informat Biometrie & Epidemiol, Essen, Germany
关键词
acute respiratory distress syndrome; protein C; thrombin; factor V Leiden;
D O I
10.1097/CCM.0b013e318174373d
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Activation of coagulation and inflammation are parts of the innate host response to infection that may contribute to organ dysfunction and death when control of these systems is compromised. Thus, functional single nucleotide polymorphisms within candidate genes of the inflammation and coagulation cascade are possible factors which may influence severity and/or mortality in acute respiratory distress syndrome. The aim of this study was to investigate whether the factor V Leiden mutation (Arg506Gln) is associated with altered severity and/or mortality in acute respiratory distress syndrome. Design: Retrospective cohort, genetic association study. Setting. Tertiary care intensive care unit. Patients., Adults (white Germans) with acute respiratory distress syndrome (n = 106). Interventions: Genotyping for the factor V Leiden mutation. Measurements, and Main Results: Using Kaplan-Meier estimates to compare outcome, 30-day survival was significantly associated with the factor V Leiden mutation (p =.049). Thirty-day survival rates were 100% for Arg/Gln (n = 7) genotypes but only 58% for Arg/Arg (n = 99) genotypes, respectively. Conclusion: We show for the first time that a heterozygous factor V Leiden genotype is associated with improved 30-day survival in patients with acute respiratory distress syndrome.
引用
收藏
页码:1776 / 1779
页数:4
相关论文
共 31 条
[21]   High frequency of factor V Leiden mutation in parsis - a highly endogamous population in India [J].
Pawar, A ;
Ghosh, K ;
Shetty, S ;
Colah, R ;
Mohanty, D .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (06) :965-965
[22]  
Pawar AR, 2001, THROMB HAEMOSTASIS, V86, P1591
[23]   The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis [J].
Svensson, PJ ;
Zoller, B ;
Mattiasson, I ;
Dahlback, B .
JOURNAL OF INTERNAL MEDICINE, 1997, 241 (05) :379-385
[24]   Endothelial cell protein C receptor plays an important role in protein C activation in vivo [J].
Taylor, FB ;
Peer, GT ;
Lockhart, MS ;
Ferrell, G ;
Esmon, CT .
BLOOD, 2001, 97 (06) :1685-1688
[25]   A MODEL FOR THROMBIN PROTECTION AGAINST ENDOTOXIN [J].
TAYLOR, FB ;
CHANG, A ;
HINSHAW, LB ;
ESMON, CT ;
ARCHER, LT ;
BELLER, BK .
THROMBOSIS RESEARCH, 1984, 36 (02) :177-185
[26]   Increased tissue factor-initiated prothrombin activation as a result of the Arg(506)->Gln mutation in factor V-LEIDEN [J].
vantVeer, C ;
Kalafatis, M ;
Bertina, RM ;
Simioni, P ;
Mann, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (33) :20721-20729
[27]   An in vitro analysis of the combination of hemophilia a and factor V-LEIDEN [J].
vantVeer, C ;
Golden, NJ ;
Kalafatis, M ;
Simioni, P ;
Bertina, RM ;
Mann, KG .
BLOOD, 1997, 90 (08) :3067-3072
[28]  
WALKER FJ, 1990, J BIOL CHEM, V265, P1484
[29]   High-dose a randomized antithrombin III in severe sepsis -: A randomized controlled trial [J].
Warren, BL ;
Eid, A ;
Singer, P ;
Pillay, SS ;
Carl, P ;
Novak, I ;
Chalupa, P ;
Atherstone, A ;
Pénzes, I ;
Kübler, A ;
Knaub, S ;
Keinecke, HO ;
Heinrichs, H ;
Schindel, F ;
Juers, M ;
Bone, RC ;
Opal, SM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (15) :1869-1878
[30]   Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies [J].
Weiler, H ;
Kerlin, B ;
Lytle, MC .
CRITICAL CARE MEDICINE, 2004, 32 (05) :S233-S238